The 6th Scientific Day of Imam Hussein Medical City has taken place in the premises of Baron Hotel in Karbala Governorate in Iraq.
The Governor of Karbala, Aqil Al-Turaihi, has participated in this event in addition to the physicians of Imam Hussein Medical City. Other physicians from various hospitals in the governorate and a big group of pharmacists were present also.
Farabi Pharma Scientific Bureau has participated in this event as an exclusive representative of the German generic manufacturer Denk Pharma in middle and south Iraq.
The most important topics that were discussed duringthis eventwere the complicated medical issues, taking up the level of the medical services in the governorate and improving the sights of Iraqi patients towards the level of medicine in Iraq.
The participants expressed their thanks for the outstanding presence by the marketing team of DenkPharma from the southern and middle Iraq. Furthermore, the Medical Manager from Farabi Pharma Headquarter in Baghdad, Dr. Zaid Adnan, has held an important presentation about the loop diuretic product TorasDenk(torsemide) that made a great deal of impact on the audience.
In Today’s world it’s encouraging to see the recognition of asthma as a global problem has increased since the first global Asthma report 2011 which was jointly published by International Union against Tuberculosis and Lung Disease and International Study of Asthma and Allergies in Childhood. In Iraq the prevalence of Asthma is 8.3 per 1000person, and prevalence between rural and urban area are
nearly the same, there is even higher prevalence in south and centre region than on Kurdistan (8.6 and 6.0 per 1000 persons respectively). The major concern is prevalence rates increases steadily with age, with greatest number of cases reported among those over 50, there is a small difference between male and female rates 8.8 ad 7.7 per 1000 respectively.
FARABI PHARMA Board member decided to support the individuals living with asthma and strongly expressed patient concerns regarding access to medicine to overcome the asthma problems in Iraq. The board decision was unanimous that being a pharma leader in Iraq and contribution to overcome the asthma problem is mandatory by simplifying the access to medicine at very affordable prices to patient. To address the awareness of the products which is used for treatment of Asthma, a symposium was jointly organized by FARABI PHARMA and Denk Pharma in collaboration with Iraqi Cardio-Thoracic Society in Baghdad which has brought together the Iraqi top - class professors, scientists and otolaryngology specialists to discuss about montelukast as a leukotriene receptor antagonist on September 23th, 2016.
The theme of the event was building connections and to glance at the medications related to Asthma, with particular attention to the product portfolio of Denk Pharma. The one day discussions enabled professionals to gain an insight into the product Montelukast and opened up networking opportunities with national otolaryngology key opinion leaders. The product is as known by physicians used for the maintenance treatment of asthma and to the patients living with severe allergies may experience significant challenges accessing this beneficial and cost-effective treatment.
Farabi Pharma and Denk Pharma brought together a panel of experts to share their experiences about ENT drugs, with the goal of increasing the understanding of these medications and how otolaryngology specialists and physicians can work with them to help patients reach their treatment goals and live healthier, happier lives. The symposium attracted also officials, scientists and academic experts.
Dr. Omar Mahmood, Country Manager of Denk Pharma/Iraq, held a presentation about establishment, the manufacturing site as well as the gluten-free products of Denk Pharma.
Dr. Mahmood Al-Obaidi, FICMS (med.), attended the event as a well-experienced moderator. He welcomed the guests and participants of the event and underlined the role of Denk Pharma and existence of Denk Pharma in Iraq.
Dr. Abdul-Hameed Al-Qaseer was the leading keynote speaker of this symposium. He talked about Leukotriene receptor antagonist LTRA Uses in Asthma.
Dr. Mustafa Nima as a keynote speaker of the symposium also talked about Asthma-COPD Overlap Syndrome ACOS.
Farabi Pharma utilized this opportunity to advertise for the medical crises to the product portfolio of Denk Pharma in general and to generate the awareness of pharmaceutical crises, various physicians, academic experts from medical colleges about Denk Pharma, quality control, packaging and registration of Denk Pharma.
The symposium has been followed by an open buffet dinner sponsored by Farabi Pharma. The dinner was also a good opportunity for the marketing team of Farabi Pharma to expand the network of connections to health specialists and to prepare for new future ideas and events to promote the distribution of Denk products in the territory.
Farabi Pharma is thankful to all the speakers who made this event a grand success, a special thanks to Denk Pharma and Iraqi Cardio - Thoracic Society, many thanks to all media partners for the promotion of this event.
"FARABI aims and wants to maintain as one of the largest and leading pharmaceutical companies in Iraq" said FARABI Chief Operating Officer, Mr. Ahmed Al-Juburi. "We want to be at the center of an ecosystem that shares our aspiration". FARABI announced today that it has selected KARRADA for its corporate headquarters location. FARABI PHARMA has moved from its Al-Sadoun Street base office where it has been situated since the late 2000's to new office at KARRADA. "This relocation comes as a result of the company's unprecedented growth over the past few years which have leaded to increase our company work force significantly. This new building will also facilitate with more efficient and effective interaction with our national sales force and our strategic partners based globally".
After over 12 years at the previous site in Al-Sadoun Street, Mushajer, FARABI PHARMA has expanded to this extent that new administration offices and warehousing facilities were essential.
at Hay Al-Wihda in Karrada with its central location in the capital city have been purpose built to meet the exact requirements of the company. The new office layout promotes communication and collaboration between employees and creates optimal conditions to inspire innovation. With this move, FARABI PHARMA further emphasizes the modernization of its corporate identity, implemented at the beginning of the year.
"This move is the latest action by FARABI board for ongoing reshaping of our business expansion and we are significantly investing more to fulfill the unmet Pharma and biological product market in Iraq. We are very excited to bring our headquarters to this dynamic and beautiful location which provides the easy accessibility both for our employees and our business partners. The move comes in light of the growth of the company. The additional capacity of the offices also falls in line with future plans to expand FARABI PHARMA", said FARABI Chief Operating Officer, Mr. Ahmed Al-Juburi.
As of 2016, the new company address shall be:
Farabi Pharma Scientific Bureau
Karrada, Hay Al-Wihda,
District 906, Zuqaq 20,
Building 23
Baghdad-Iraq
Inquiries
Farabi Pharma Scientific Bureau
Tel: 00964 7827 300 163
Email: info@farabipharma.net
Website: www.farabipharma.net
FARABI PHARMA announced a five-year exclusive agreement with DENK PHARMA for the distribution of the product portfolio of DENK PHARMA in whole Iraq (except the federal region of Kurdistan-Iraq). The agreement would help DENK PHARMA to build its presence in the Iraqi generics market.
With this agreement, DENK PHARMA granted Farabi Pharma exclusive right to import, register, advertise, warehouse, distribute and sell a number of generic products (including life-saving medications) of DENK PHARMA in the territory of Iraq.
Ahmed Al-Juburi, COO & Business Development Director of FARABI PHARMA, said: "We are excited to enter into an exclusive distribution agreement with DENK PHARMA for selected generic products. We will strive to position DENK PHARMA as a trusted generic brand in the Iraqi market and make a success story with its esteemed products.
Furthermore, we are planning to expand in 2016 this cooperation with DENK PHARMA and introduce the food supplements portfolio of DENK PHARMA in the territory" DENK PHARMA is a German pharmaceutical company delivering high quality generics, manufactured, registered and quality-controlled in Germany.
DENK PHARMA was founded in Munich, Germany in 1948. With a strong focus on export markets, DENK PHARMA presently supplies a wide range of premium medicine and food supplements to over 70 countries worldwide. DENK PHARMA has created something unique. All DENK PHARMA products are: Manufactured, quality controlled and registered in Germany.
DENK PHARMA's premium medicine is not only registered but also approved for the German market by the German Health authorities.
The DENK PHARMA production facility is state-of-the-art and of course meets the latest requirements with respect to GMP and ISO.
On May 29th, 2016 a SYMPOSIUM has been jointly organized by FarabiPharma and DenkPharma in collaboration with the Iraqi Cardio - Thoracic Society in Baghdad which has brought together the Iraqi top -class professors, scientists and cardiologists to discuss the innovative medicine which is used for the management of fluid retention in heart failure. The theme of the event was building connections and to glance at the medications related to heart failure, with particular attention to the cardiovascular drugs of DenkPharma.Theone day discussions enabled professionals to gain an insight into the current innovations and opened up networking opportunities with national cardiology key opinion leaders
FarabiPharma believes that building connections within cardiovascular specialists is of great importance to the health sector in Iraq, patients with heart diseases, academic community and caregivers of patients to the health institutions which serve them.
FarabiPharma and DenkPharma brought together a panel of experts to share their experiences about cardiovascular drugs, with the goal of increasing the understanding of these medications and how heart specialists and physicians can work with them to help heart patients reach their treatment goals and live healthier, happier lives.
The symposium attracted also officials from Iraqi Ministry of Health, many other physicians from various health fields, chairmen of universities and academic experts.
Dr. Omar Mahmood, Country Manager of DenkPharma/Iraq, held a presentation about establishment, the manufacturing site as well as the gluten-free products of DenkPharma.
Dr. Mahmood Al-Obaidi, FICMS (med.), attended the event as a well-experienced moderator. He welcomed the guests and participants of the event and underlined the role of DenkPharma and Iraqi Cardio - Thoracic Society in supporting the symposium which has been held under the aegis of both sides.
Dr. EdmonKh. Benjamin, FICMS (med.), FICMS (cardiol.), was the leading keynote speaker of this symposium. He talked about heart failure (HF) and symptoms of HF as well as how to manage fluid retention in HF by using torasemide as well as conditions for prescription of torasemide and compared this drug with other usual diuretics.
FarabiPharma utilized this opportunity to advertise for more cardiac medications and to the product portfolio of DenkPharma in general and to generate the awareness of pharmaceutical crises, various physicians, academic experts from medical colleges and the officials of Iraqi Ministry of Health about DenkPharma, quality control, packaging and registration of DenkPharma.
The symposium has been followed by an open buffet dinner sponsored by FarabiPharma. The dinner was also a good opportunity for the marketing team of FarabiPharma to expand the network of connections to health specialists and to prepare for new future ideas and events to promote the distribution of Denk products in the territory.
The highlights of the meeting were the eponymous lectures and awareness;these talks were of great interest to the general cardiologists and were enormously informative for these newly launched molecules.
FarabiPharma is thankful to all the speakers who made this event a grand success, a special thanks to Iraqi MOH, DenkPharma and Iraqi Cardio - Thoracic Society, many thanks to all media partners for the promotion of this event.